Karyopharm Therapeutics Inc. (KPTI) Discusses Top Line Results From Phase III SENTRY Trial in Myelofibrosis Transcript

PresentationOperator Good morning. My name is Jenny, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics' call to discuss top line results from the Phase III SENTRY trial. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the conference call over to Brendan Strong, Senior Vice President, Investor Relations. ...